Unknown

Dataset Information

0

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).


ABSTRACT: Anaplastic lymphoma kinase (ALK) inhibitors have demonstrated robust clinical activity in patients with ALK-rearranged lung cancers. The echinoderm microtubule-associated protein-like (EML)-ALK translocation was first discovered in 2007 and 4 years later, crizotinib, a first-generation ALK inhibitor was approved. Since then, subsequent generations of ALK inhibitors have demonstrated superior efficacy and better CNS activity compared to crizotinib. Alectinib and brigatinib, both second-generation ALK inhibitors have been compared directly to crizotinib in the first-line setting and has demonstrated improved progression free survival (PFS) and intracranial response. Ceritinib, another second-generation ALK inhibitor has been shown to be superior to chemotherapy in ALK-rearranged disease with good CNS activity. Initial responses to ALK inhibitors are not always durable and resistance can occur as on-target or off-target alterations. Lorlatinib, a third-generation ALK inhibitor, has demonstrated activity in the treatment naïve setting and in resistance to crizotinib and second-generation ALK inhibitors. Lorlatinib has also shown improved PFS in patients harboring EML4-ALK variant 3, which is associated with the development of ALK resistance mutations, specifically G1202R. Another new ALK inhibitor, ensartinib, has demonstrated efficacy in the first-line setting and in alectinib refractory disease. Additional studies are underway examining mechanisms of resistance and best treatment options post resistance.

SUBMITTER: Xia B 

PROVIDER: S-EPMC7815371 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

How to select the best upfront therapy for metastatic disease? Focus on <i>ALK</i>-rearranged non-small cell lung cancer (NSCLC).

Xia Bing B   Nagasaka Misako M   Zhu Viola W VW   Ou Sai-Hong Ignatius SI   Soo Ross A RA  

Translational lung cancer research 20201201 6


Anaplastic lymphoma kinase (ALK) inhibitors have demonstrated robust clinical activity in patients with <i>ALK</i>-rearranged lung cancers. The echinoderm microtubule-associated protein-like (<i>EML</i>)-<i>ALK</i> translocation was first discovered in 2007 and 4 years later, crizotinib, a first-generation ALK inhibitor was approved. Since then, subsequent generations of ALK inhibitors have demonstrated superior efficacy and better CNS activity compared to crizotinib. Alectinib and brigatinib, b  ...[more]

Similar Datasets

| S-EPMC7815342 | biostudies-literature
| S-EPMC9407780 | biostudies-literature
| S-EPMC5127851 | biostudies-literature
| S-EPMC4079055 | biostudies-literature
| S-EPMC6343825 | biostudies-literature
| S-EPMC7439864 | biostudies-literature
| S-EPMC3477548 | biostudies-literature
| S-EPMC4369851 | biostudies-literature
| S-EPMC9795041 | biostudies-literature
| S-EPMC10713259 | biostudies-literature